Peptide Library

FDA-approved

Heart & blood

Rusfertide

Evidence

FDA approved

Class

Hepcidin mimetic peptide

/

Rusfertide

KEY TAKEAWAY

Rusfertide is a synthetic peptide that mimics hepcidin, the hormone that regulates iron in the body. It is sold as Mimrylo. The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Hepcidin mimetic peptide

Approved for

Erythrocytosis in adults with polycythemia vera

Key fact

The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.

Route

Weekly subcutaneous injection

Evidence strength

FDA approved

What it is

What it is

Rusfertide is a synthetic peptide that mimics hepcidin, the hormone that regulates iron in the body. It is sold as Mimrylo.

How it works

How it works

It limits the iron available to make new red blood cells, which reduces overproduction of red cells.

Regulatory status

Regulatory status

The FDA approved rusfertide (Mimrylo) on August 28, 2026 for adults with polycythemia vera.

What it is used for

What it is used for

Erythrocytosis in adults with polycythemia vera.

Side effects and risks

Side effects and risks

Injection-site reactions and anemia were the most common adverse reactions.

Citations

Citations

U.S. FDA prescribing information for Rusfertide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo